Facebook Twitter LinkedIn Instagram Email Printer Google Plus

Pharma

And How Stakeholders Can, Literally, Save the World

Climate change will be the biggest impact on global health. The healthcare industry may not respond in time.

Director, Marsh & McLennan Advantage Insights
Partner, Health and Life Sciences, Oliver Wyman

In our rearview mirror is a ten-year stretch of experimentation. What looms ahead is the rewriting of healthcare's rules.

Partner, Health and Life Sciences, Oliver Wyman
Former Partner, Health & Life Sciences, Oliver Wyman
Principal, Health and Life Sciences, Oliver Wyman

Whoever's closest to the consumer will be the gatekeeper of the industry.

Principal, Health and Life Sciences, Organizational Effectiveness, Oliver Wyman
Principal, Oliver Wyman
Senior Consultant, Oliver Wyman

A closer look at how fast change may happen, who could win (and lose), and how the next decade may unfold for incumbents and new market entrants.

Partner, Health and Life Sciences, Oliver Wyman
Senior Knowledge Expert, Oliver Wyman

Physicians are best positioned to curtail the $265 billion wasted annually on unneeded care.

Global Head, Health Services, Oliver Wyman
Professor of Surgery and Health Policy, Johns Hopkins Medicine
Principal, Health and Life Sciences, Oliver Wyman

Insights in your inbox

Subscribe

Our most popular articles of the year offered our predictions on disruption and the future market, and highlighted our views on healthcare reform, ACOs, and much more.

How pharmaceutical companies can better define, measure, and deliver value to patients.

Director, Marsh & McLennan Advantage, Healthcare
Engagement Manager, Health & Life Sciences, Oliver Wyman

What's around the bend for healthcare venture capital in 2018? We talk Amazon, good and bad M&A, and hitting the investment peak.

Senior Managing Director, GE Ventures

As one of the fastest-rising categories of healthcare costs, pharmaceuticals need to develop a metric that explains pricing.

Partner, Health & Life Sciences, Oliver Wyman
Principal, Health & Life Sciences, Oliver Wyman

How a “sticky” consumer experience could help control the drain of high-cost chronic disease drugs.

Partner, Health and Life Sciences, Oliver Wyman

Insights in your inbox

Subscribe